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A B S T R A C T
Background: Multiple sclerosis (MS) is an autoimmune disease characterized by inﬂammation and axonal
degeneration of the central nervous system and a leading cause of disability in young adults. The matrix
metalloproteinases in general and specially gelatinase B/metalloproteinase-9 (MMP-9) plays a role in the
pathogenesis of multiple sclerosis.
Objective: To investigate the presence of the MMP-9 −1562 C/T polymorphism in a Portuguese population of
MS patients and assess its impact in susceptibility and course of the disease. The relation of MMP-9 serum
levels with the polymorphism and with clinical and therapeutic factors will also be assessed.
Methods: Our study included 355 Caucasian individuals distributed as MS patients (n=169) and controls
(n=186). Samples were genotyped for −1562 C/T polymorphism by PCR-RFLP analysis. MMP-9 concentration
in serum was analyzed using a commercially available enzyme-linked immunosorbent assay.
Results: A signiﬁcant increase in T-allele frequency was found in female MS patients, but not in the total
patient population. No association between the presence of the polymorphism and disease progression was
found. MMP-9 serum concentrations were increased in patients, and although not inﬂuenced by the −1562 C/T
polymorphism, were modiﬁed by INF-beta therapy.
Conclusion: Although we did not ﬁnd an association of this polymorphism with disease susceptibility or
prognosis, MMP-9 appears to be a good therapeutic response marker for multiple sclerosis.
1. Introduction
Multiple sclerosis (MS) is a progressive autoimmune disease
characterized by inﬂammation, demyelination, and axonal degenera-
tion, resulting in the interruption of myelinated tracts of the central
nervous system (CNS) and a leading cause of disability in young adults.
The heterogeneous clinical course of the disease and underlying
pathophysiological mechanisms, make MS prognosis extremely chal-
lenging to deﬁne (Hauser and Oksenberg, 2006).
Although the etiology of the disease remains unclear, an auto-
immune reaction directed against antigens of cerebral white matter has
been proved (Hartung et al., 2004) and the migration of autoreactive
immune cells through the blood-brain barrier (BBB) into the CNS
seems crucial for the formation of inﬂammatory lesions (Martin et al.,
2000). An important role in this process is played by matrix metallo-
proteinases (MMPs). In particular, gelatinase B/MMP-9, has been
demonstrated to facilitate the inﬂux of inﬂammatory cells into the CNS
(Gijbels et al., 1993; Lee et al., 1999), as well as, the BBB breakdown
(Chandler et al., 1995; Gijbels et al., 1993) and to cleave human myelin
basic protein in vitro (Proost et al., 1993). MMPs are secreted by a wide
range of cell types, capable of degrading all protein components of the
extracellular matrix (Chandler et al., 1995; de Souza et al., 2005). The
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activity of the MMPs is regulated at diﬀerent levels (Yong et al., 2001;
Yushchenko et al., 2003), such as gene expression, proenzyme activa-
tion, and by the activity of the tissue inhibitors of matrix metallopro-
teinases (TIMPs). The transcriptional activity of the MMP-9 gene
(located in chromosome 20q13) is inﬂuenced by two polymorphisms
identiﬁed in the promoter region. These are a CAn microsatellite
polymorphism from position −90 (St Jean et al., 1995) and a single
nucleotide polymorphism at position -1562 caused by a C to T
substitution (Zhang et al., 1999). In vitro studies have shown that this
substitution prevents the binding of a nuclear transcription repressor
protein to this region of the MMP-9 gene promoter, being associated
with increased MMP-9 expression (Zhang et al., 1999). On this basis, it
is reasonable to hypothesize that both −1562T and the longest repeat
alleles may be highly plausible genetic risk factors for MS and there-
fore, there has been considerable research interest in the possible
association of variations in the MMP-9 gene and MS susceptibility.
A few studies have addressed the involvement of the −1562 C/T
polymorphism, alone or in combination with the CAn microsatellite
polymorphism, with susceptibility to MS (Benesova et al., 2008; Fiotti
et al., 2004; Nelissen et al., 2000; Zivkovic et al., 2007). Despite
controversial results (La Russa et al., 2010; Mirowska-Guzel et al.,
2009), it is generally accepted that the −1562 C/T polymorphism has
no impact on susceptibility to MS (Nischwitz et al., 2015), but its
possible inﬂuence on disease course is still largely unknown.
At protein level, both gelatinase B/MMP-9 increased concentration
(Gijbels et al., 1992; Lee et al., 1999) and activity (Avolio et al., 2003;
Liuzzi et al., 2002) in serum and in the cerebrospinal ﬂuid (CSF) of MS
patients, compared to controls, have been well established. In fact, this
MMP has been suggested as a useful marker for the evaluation of the
clinical type, disability and severity of MS (Benesova et al., 2009).
However, the relation between MMP-9 levels in peripheral blood and
the −1562 C/T and CAn microsatellite polymorphisms has been
addressed only in two small studies (Fernandes et al., 2012;
Mirowska-Guzel et al., 2009).
MMP-9 has also been considered a therapeutical response biomar-
ker for interferon-beta (IFN-beta), a common immunomodulatory
ﬁrst-line treatment employed in MS. In fact, serum MMP-9 concentra-
tion decrease with IFN-beta therapy (Alexander et al., 2010; Comabella
et al., 2009; Yilmaz et al., 2012), correlating with the decrease of active
lesions during treatment (Avolio et al., 2005; Trojano et al., 1999).
The aim of our study was to investigate the presence of the
−1562 C/T polymorphism in the MMP-9 gene in a Portuguese popula-
tion of MS patients, and assess its impact in MS course. We also
evaluated serum concentration of MMP-9, and their relation with the
−1562 C/T polymorphism, as well as with clinical and therapeutical
factors.
2. Materials and methods
2.1. Subjects
This study comprised 355 Caucasian individuals originated from
Portugal that represent a genetically stable and homogenous popula-
tion. MS patients (n=169) were recruited at the Neurology Department
of the Centro Hospitalar e Universitário of Coimbra (CHUC)-Coimbra,
Portugal and the Braga Hospital-Braga, Portugal. MS was diagnosed
according to the McDonald and Polman criteria (McDonald et al.,
2001; Polman et al., 2011) and all patients had a minimum clinical
follow-up time, of two years. Information regarding patient gender, age
at onset, disease duration, initial symptoms (optical vs other path-
ways), subtypes (relapsing-remitting-RR; secondary progressive-SP;
primary progressive-PP), severity (estimated using the Expanded
Disability Status Scale-EDSS), (Kurtzke, 1983) and treatment, were
retrieved from local MS database or individual medical records and
included in the analysis. All MS patients had been treated with ﬁrst-line
therapy only (59.7%; including IFN-beta and glatiramer acetate) or
with second-line therapy (40.3%; including ﬁngolimod and natalizu-
mab) (Kerbrat et al., 2015). At time of blood collection, 60% of patients
were undergoing therapy with IFN-beta, and all RR patients were in
remission.
The control group included 186 unrelated healthy volunteers,
matched for age, gender and ethnicity. The study protocol was
approved by the Hospital (CHUC) Ethics Committee. All participants
in this study provided written informed consent.
2.2. Genotyping
Blood samples were collected with EDTA tubes, and genomic DNA
was extracted using a standard procedure (Spin Blood Mini Kit,
Invisorb®, Stratec molecular - Berlin). The polymorphism at position
−1562 C/T (rs3918242 deposited in the NCBI database) in MMP-9
gene promoter was genotyped by PCR-restriction fragment length
polymorphism (RFLP) analysis. PCR ampliﬁcation, was performed
using the primers 5’-ATGGCTCATGCCCGTAATCC-3’ (forward) and
5’-GGGCAGGGTCTATATTCACC-3’ (reverse), as previously described
by (Fernandes et al., 2009; Zhang et al., 1999). The ampliﬁed products
were digested with SphI (Thermo Scientiﬁc, USA), overnight at 37 °C,
producing fragments of 224 and 124 bp (T allele) or an undigested
fragment of 348 bp (C allele). Fragments were then separated by
electrophoresis in 2% agarose gel and visualized through ethidium
bromide.
2.3. MMP-9 concentration in serum
MMP-9 concentration in serum (both 92 kDa Pro- and 82 kDa
active forms) of 96 MS patients and 63 controls was measured using a
commercially available enzyme-linked immunosorbent assay (ELISA),
according to the manufacturer's instructions (Quantikine Human
MMP-9 Immunoassay, R &D Systems Europe, Ltd. UK).
2.4. Statistical analysis
Statistical analysis was performed using SPSS version 21.0 (IBM).
Diﬀerences in both allele and genotype frequencies distribution
between study groups as well as deviation from Hardy-Weinberg
equilibrium were estimated by χ2 test. Hardy-Weinberg equilibrium
was evaluated using a Hardy-Weinberg test Equilibrium Calculator for
2 Alleles (Emerson, 2010). Diﬀerences in demographic, clinical vari-
ables and MMP-9 serum concentration between groups were compared
using the Mann-Whitney U test (two groups) or the Kruskal Wallis test
(three groups) for continuous variables or the Pearson chi-square (χ2)
test for categorical variables. A two-way ANOVA was used for establish-
ing interactions between diagnosis and MMP-9 genotype. Binary
logistic regression models, controlled for age and gender were used
to assess the contribution of clinical variables in predicting the
−1562 C/T polymorphism carrier status. Survival analysis was used
to assess the inﬂuence of the −1562 C/T polymorphism in the prob-
ability of reaching an EDSS ≥ 3, previously deﬁned as indicative of
moderate disability (Kerbrat et al., 2015; Leray et al., 2010). Kaplan-
Meier survival curves were plotted and the survival distributions
according to the presence or absence of the T allele were compared
by the log-rank test. Survival time was calculated as the interval from
the initial baseline evaluation to the time to reach an EDSS of 3. For
patients who did not reach this score, survival time was censored at the
date of the last clinical assessment. The results were presented as mean
± standard error (SEM) and p ≤ 0.05 was considered statistically
signiﬁcant.
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3. Results
3.1. Sample characterization and −1562 C/T polymorphism
distribution
Demographic and clinical characteristics of MS patients and con-
trols are summarized in Table 1. There were no signiﬁcant diﬀerences
in the age and gender distribution between patients and controls.
Genotype distribution of the −1562 C/T polymorphism, was not
statistically diﬀerent between patients (130CC; 35CT; 4TT) and con-
trols (145CC; 37CT; 4TT) and, did not deviate from the Hardy-
Weinberg equilibrium in any group. 77% and 78% of patients and
controls presented the CC genotype, respectively, and only 2% of
patients and controls were homozygous for T allele.
3.2. Genotype, gender and clinical factors
Genotype distribution of the −1562 C/T in patients and controls
divided by gender are shown in Table 2. Since the TT genotype
frequency is very low (only four cases in both groups), CT and TT
carriers were grouped (CT+TT). In the control group, genotype and
allelic frequency did not reveal diﬀerences between males and females.
However, in patients, the frequency of the T allele was 15.7% in females
vs 5.2% in males (p=0.040) and of the CT+TT genotype was 28.1% in
females vs 10.4% in males (p=0.014). In fact, none of the male MS
patients was homozygous for the T allele, whereas in the control
population one out of the four TT cases was a male.
Next, we analyzed the possible inﬂuence of the −1562 C/T poly-
morphism in the disease course. Table 3 shows age of disease onset,
duration of MS, EDSS, initial symptoms, subtypes, conversion from RR
to SP and therapy, in patients according to T carrier status (CC vs CT
+TT genotype).
Overall, there were no statistically signiﬁcant diﬀerences between
groups. To further explore the possible association between the MMP-9
polymorphism and disease course in patients, a logistic regression
model was applied, but none of the tested clinical variables (age of
disease onset, duration of MS, initial symptoms, subtypes, EDSS and
treatment) could independently predict the presence of the −1562 C/T
polymorphism. In fact, the only variable that showed an association
with this polymorphism was, again, gender (p=0.049). Moreover,
Kaplan-Meier survival curves for the probability of reaching an EDSS
≤ 3 were plotted according to the −1562 C/T polymorphism carrier
status (not shown). 38% of T non-carriers and 26% of T carriers
reached an EDSS ≥ 3 during follow-up, but there was no statistical
diﬀerence in the time to reach this severity score (CC genotype=184 ±
15 months; CT+TT genotype=346 ± 38 months; χ2 (1)=1.804;
p=0.179).
3.3. Serum gelatinase B/MMP-9 concentration, genotype and clinical
factors
Serum gelatinase B/MMP-9 concentration was determined in a
subgroup of the study population (63 controls; 96 patients), as shown
in Fig. 1. In this subpopulation, MS patients were slightly older than
controls (43.92 ± 1.14 years vs 39.79 ± 1.77 years; p=0.043), but no
diﬀerences in gender distribution were seen. Clinical characteristics of
Table 1
Characterization of patients and controls.
MS C
n=169 n=186
Age, years 41.44 ± 0.84 39.09 ± 0.96
(min-max) (17–69) (20–74)
Gender 121/48 122/64
(Female/male)
Subtypes 143;20;6 –
(RR;SP;PP)
Age of onset, years 32.19 ± 0.78 –
(min-max) (8–56)
Duration of MS, years 11.84 ± 0.64 –
(min-max) (2–43)
EDSS 2.95 ± 0.14 –
(min-max) (0–8.0)
The data are presented as mean ± standard error.
MS-multiple sclerosis; C-controls; RR-relapsing-remitting.
SP-secondary progressive; PP-primary-progressive.
EDSS-Expanded Disability Status Scale.
Table 2
Genotype distribution of the −1562 C/T polymorphism in patients and controls by
gender.
-1562 C/T Genotype MS C
MMP-9 n (%) n (%)
Total CC 130 (76.9%) 145 (77.9%)
CT+TT 39 (23.1%) 41 (22.1%)
Female CC 87 (71.9%) 98 (80.3%)
CT+TT 34 (28.1%)* 24 (19.7%)
Male CC 43 (89.6%) 47 (73.4%)
CT+TT 5 (10.4%) 17 (26.6%)
MS-multiple sclerosis; C-controls.
* p≤0.05 female vs male in patients.
Table 3
Relation of the −1562 C/T polymorphism with clinical factors in MS patients.
CC CT+TT
n=130 n=39
Age of onset, years 32.07 ± 0.88 32.59 ± 1.71
(min-max) (8–56) (17–54)
Duration of MS, years 12.07 ± 0.73 10.82 ± 1.22
(min-max) (2–43) (2–40)
EDSS 3.05 ± 0.17 2.62 ± 0.25
(min-max) (0–8.0) (0–7.5)
Initial symptoms (22/78)% (12/88)%
(optical/other pathways)
Subtypes 107;18;5 35;3;1
(RR;SP;PP)
Conversion RR-SP (18/82)% (8/92)%
(Y/N)
Therapy (50/50)% (47/53)%
(ﬁrst-line/second-line)
The data are presented as mean ± standard error. RR-relapsing-remitting; SP-secondary
progressive; PP-primary-progressive; EDSS-Expanded Disability Status Scale.
C
Fig. 1. Serum MMP-9 concentration in a subgroup of the study population (63 controls-
C; 96 MS) according to the distribution of genotypes (CC, CT+TT). The horizontal lines
indicate the mean concentration of MMP-9 in controls and MS patients.
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this MS subgroup (not shown) were similar to the total patient
population depicted in Table 1.
As expected, mean serum MMP-9 concentration was signiﬁcantly
higher in patients compared to controls (545.19 ± 34.42 ng/mL vs
401.10 ± 31.82 ng/mL; p=0.002). Taking into account the −1562 C/T
polymorphism, the two-way ANOVA showed that there was a signiﬁ-
cant eﬀect of diagnosis (p=0.001) and no signiﬁcant eﬀect of genotype
in serumMMP-9 concentration (p=0.079), with no interaction between
these two factors (p=0.178). In patients, MMP-9 serum concentration
was not inﬂuenced by the presence of the T allele, but in the control
group, the presence of the T allele was signiﬁcantly associated with
increased concentration of MMP in serum (p=0.008). MMP-9 serum
concentration in patients was also not inﬂuenced by gender (fe-
males=536.92 ± 35.58 ng/mL vs males=573.02 ± 92.38 ng/mL;
p=0.538).
The relation between MMP-9 serum concentration and disease
course is depicted in Fig. 2.
There were no diﬀerences in MMP-9 serum concentration asso-
ciated with MS patient's initial symptoms, subtypes, conversion from
RR to SP or disease severity (assessed through reaching an EDSS ≥ 3).
There was however a signiﬁcantly lower MMP-9 concentration in
patients currently undergoing IFN-beta therapy (with IFN-beta ther-
apy=470 ± 39 ng/mL vs without IFN-beta therapy =634 ± 57 ng/mL;
p=0.009). A trend for an association between higher MMP-9 serum
concentration with the necessity of second-line therapy was also seen,
but failed to reach statistical signiﬁcance (patients submitted to
second-line therapy=594 ± 36 ng/mL vs patients submitted only to
ﬁrst-line therapy=466 ± 79 ng/mL; p=0.05). Moreover, MMP-9 serum
concentration was not correlated with age of disease onset, duration of
MS, or EDSS (not shown).
4. Discussion
In the present study, our results showed that the −1562 C/T
polymorphism presented a very similar distribution between patients
and controls. However, an increase in the T allele frequency was found
in female patients compared to male patients. As expected, MMP-9
serum concentration was increased in patients, and despite not being
inﬂuenced by the −1562 C/T polymorphism, it was modulated by INF-
beta therapy.
The MMP-9 −1562 C/T genotype distribution in our patient
population (77% CC; 21% CT; 2% TT) is very similar to what has been
described in other MS cohorts from Czech Republic, Brazil or Servia
(Benesova et al., 2008; Fernandes et al., 2009; Zivkovic et al., 2007).
On the contrary, patients from Italy or Poland were reported to have a
much higher T allele frequency (32–45%) (La Russa et al., 2010;
Mirowska-Guzel et al., 2009). In our population, the presence of
−1562 C/T polymorphism did not reveal susceptibility for MS devel-
opment, conﬁrming some previous ﬁndings (Fernandes et al., 2009;
Zivkovic et al., 2007) and in agreement with a recent meta-analysis
(Nischwitz et al., 2015). However, our results diverge from other
studies ﬁnding a decrease (Benesova et al., 2008) or an increase of the
T allele in MS patients (La Russa et al., 2010; Mirowska-Guzel et al.,
2009).
When we stratiﬁed our population by gender, a signiﬁcant increase
in T allele frequency and CT+TT genotype distribution was found in
female patients compared to male patients. Besides, comparing the
distribution between female patients and controls, we found a slight
increase of the T allele in female patients compared to female controls.
This result contrasts with other studies, some of which found a
signiﬁcant decrease of T alleles in female patients compared to female
controls (Benesova et al., 2008; Nischwitz et al., 2015; Zivkovic et al.,
2007), and others reporting no signiﬁcant diﬀerences in allele dis-
tributions between female or male patients with MS and healthy
volunteers (La Russa et al., 2010; Mirowska-Guzel et al., 2009). Our
results need, however, to be interpreted with caution, as the increased
risk and incidence of females in MS may interfere with the results. In
fact, over two thirds of our MS patients and controls were females,
resulting in an overrepresentation of this group in the study popula-
tion. Moreover, as the T allele frequency is quite low in our population,
and the size of our sample is not very large, the association we found
between the −1562 C/T polymorphism and the female gender, could be
Fig. 2. MMP-9 serum concentration was determined in a subgroup of MS patients (n=96) in relation to initial symptoms (A), subtypes (B), EDSS < 3; ≥ 3 (C), conversion from RR to
SP (D), therapy (E) and IFN-β therapy (F). Data are expressed as mean ± SEM. RR-relapsing-remitting; SP-secondary progressive; PP-primary-progressive; EDSS-Expanded Disability
Status Scale.
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actually related to a female prevalence in the genotyped groups and not
to intrinsic gender characteristics.
The inconsistency of results obtained in diﬀerent studies could
either be due to true genetic variability among diﬀerent populations or
false positive and false negative ﬁndings. In particular, population
stratiﬁcation, misclassiﬁcation and inappropriate statistical methods
represent possible causes of false positive results (Abou-Sleiman et al.,
2006). Moreover, diﬀerences in study design and data analysis could
account for the discrepancy between studies. In addition, as MS
prevalence decreases from the poles to the equator the presence of
MS genetic risk factors might occur at higher frequency in northern
europeans (Hauser and Oksenberg, 2006). Therefore, further studies
on the regional-variants of putative MS susceptibility genes are still
required.
In our work, we did not ﬁnd any signiﬁcant association between the
−1562 C/T polymorphism and any of the considered clinical variables
in MS patients (age of onset, duration of MS, initial symptoms, disease
subtypes, severity and treatment). A few other studies have addressed
this issue, and also did not ﬁnd any diﬀerences in MS disability status,
subtypes, age at onset or disease duration among the genotypes
(Benesova et al., 2008; La Russa et al., 2010; Mirowska-Guzel et al.,
2009; Zivkovic et al., 2007). On the contrary, in the work of Fernandes,
although the genotype was not associated with MS, an association
between the TT genotype and a high disability score was observed
(Fernandes et al., 2009).
The second part of our study regarding MMP-9 concentration in
serum, conﬁrmed that patients have higher concentration than con-
trols, as previously reported by others (Avolio et al., 2003; Benesova
et al., 2009; Liuzzi et al., 2002). MMP-9 concentration was not
inﬂuenced by the −1562 C/T polymorphism neither in the total
population nor in patients. However, in controls, MMP-9 concentration
was higher in T allele carriers. This association between MMP-9
concentration and −1562 C/T polymorphism has only been previously
assessed in two small studies. In the study of Mirowska-Guzel, MMP-9
concentration in peripheral blood was assessed by ELISA in a very
small cohort of MS patients (n=15) and a higher concentration was
found in T allele carriers (Mirowska-Guzel et al., 2009). Fernandes and
collaborators (2012) evaluated plasma MMP-9 activity by zymography
and showed higher activity in patients carrying the polymorphism.
However, control subjects displayed equal MMP-9 activity among
genotypes (Fernandes et al., 2012). A direct comparison with our
study is diﬃcult to establish, either due to the small number of patients
studied in these previous studies, or to the diﬀerent methodology and
type of samples used (serum vs. plasma). In fact, it has been suggested
that MMP-9 is released by platelets or leucocytes during serum
producing clothing process, thus leading to an overestimation of
MMP-9 in serum, that does not correlates to MMP-9 plasma levels in
healthy individuals (Gerlach et al., 2007). However, in disease condi-
tions, it was shown that a good correlation exists between serum and
plasma concentrations of MMP-9, therefore validating the use of serum
sample analysis of MMP-9 in clinical studies (Gerlach et al., 2009).
Our results indicate that, in a physiological situation, the −1562 C/
T polymorphism is involved in the regulation of MMP-9 with the C-T
substitution being associated with increased MMP-9 expression.
However, in patients, this association is lost, and MMP-9 serum
concentration becomes independent from this polymorphism. One
possible explanation for this fact is that a large proportion of our
patients (over 50%) were medicated with IFN-beta, which is, as
discussed below, known to target MMP-9. Indeed IFN-beta therapy
was associated with a reduction in MMP-9 concentration in our patient
population. It is therefore possible that our results have been somehow
biased by the inﬂuence of the therapeutic agents. If our MS cohort
consisted of patients not yet submitted to IFN-beta therapy, the
increase in MMP-9 concentration in relation to controls could be even
more pronounced and the outcome regarding the inﬂuence of the
polymorphism could be diﬀerent.
We did not ﬁnd any diﬀerences in MMP-9 serum concentration in
patients in relation to gender, initial symptoms, subtypes or conversion
from RR to SP. Furthermore no correlation was seen between MMP-9
serum concentration and age of disease onset or disease duration.
Although higher MMP-9 serum concentration was seen in patients
undergoing second-line therapy and in patients presenting an EDSS ≥
3 (patients with EDSS < 3: 500.04 ± 44 ng/mL vs patients with EDSS ≥
3: 585.03 ± 52 ng/mL), they both failed to reach statistical signiﬁcance.
Interestingly, our results have some similarity with the results from
Fernandes and collaborators (2012). In their study, when MS partici-
pants were analyzed for drug resistance, patients with more than 2
relapses within 2 years, classiﬁed as resistant to ﬁrst-line therapy,
presented signiﬁcantly higher plasma MMP-9 activity, compared to
responsive patients. Besides, a correlation was seen between plasma
MMP-9 activity and EDSS (Fernandes et al., 2012).
Our study, in line with others, have shown that therapy with IFN-
beta induces a decrease in MMP-9 levels (Alexander et al., 2010;
Comabella et al., 2009; Galboiz et al., 2001; Yilmaz et al., 2012) as well
as an increase in TIMP-1 levels (Alexander et al., 2010; Comabella
et al., 2009; Galboiz et al., 2001) contributing to restore BBB integrity.
This mechanism might ultimately correlate with the clinical stabiliza-
tion found in RR patients that respond to IFN-beta therapy (Comabella
et al., 2009). Second-line therapy does not act at MMP-9 level (Du
Pasquier et al., 2014) and this could explain the increase in MMP-9
concentration in patients submitted to second-line therapy. As second-
line therapies are known to be more eﬀective in controlling disease
activity and disability progression, a signiﬁcant correlation between
EDSS and MMP-9 concentration might have been concealed.
This study has some important limitations such as the small
number of analyzed patients/controls, especially for determination of
MMP-9 serum concentration, which could have a strong impact in
results consistency and also explain the discrepancies in relation to the
existing literature. The study design, including a heterogeneous MS
population evaluated by diﬀerent clinicians and submitted to diﬀerent
therapeutic schemes potentially biased the results and could be
improved in the future. Nevertheless, the population was well char-
acterized concerning demographical and clinical variables known to
inﬂuence disease progression and the possible associations with MMP-
9 concentration/polymorphism were thoroughly explored.
5. Conclusion
To our knowledge, this is the ﬁrst study done in the Portuguese
population assessing MMP-9 serum concentration and the MMP-9
−1562 C/T polymorphism in MS patients.
Although we did not ﬁnd any evidence for an association of MMP-9
−1562 C/T polymorphism with disease susceptibility or prognosis, a
signiﬁcant increase in T allele frequency in female patients was shown.
Ultimately, MMP-9 appears to be a good therapeutical response
marker for patients with MS treated with interferon beta.
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